Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3H2184
Fri, 23.12.2022       Epigenomics AG
DE000A3H2184

Pareto Securities AS publishes buy recommendation for Epigenomics AG share Berlin (Germany), December 23, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG's share and issuing a buy recommendation. Pareto's analyst [ … ]
Technical analysis
To the publication
Fri, 23.12.2022       Epigenomics AG
DE000A3H2184

Pareto Securities AS publishes buy recommendation for Epigenomics AG share Berlin (Germany), December 23, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG's share and issuing a buy recommendation. Pareto's analyst [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics Releases Performance Data on Next Generation Test Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing. Performance exceeds on-market standard of FIT testing for CRC screening. Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics Releases Performance Data on Next Generation Test Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing. Performance exceeds on-market standard of FIT testing for CRC screening. Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test Combined technologies have the potential to create a high-performance, cost-effective, blood-based CRC testing solution Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prim [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Epigenomics AG
DE000A3H2184

Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test Combined technologies have the potential to create a high-performance, cost-effective, blood-based CRC testing solution Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prim [ … ]
Technical analysis
To the publication
Wed, 09.11.2022       Epigenomics AG
DE000A3H2184

Epigenomics AG reports financial results for the first nine months 2022   Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022. Key figures Total revenue decreased to EUR 386 thousand in 9M 2022,  [ … ]
Technical analysis
To the publication
Wed, 09.11.2022       Epigenomics AG
DE000A3H2184

Epigenomics AG reports financial results for the first nine months 2022   Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022. Key figures Total revenue decreased to EUR 386 thousand in 9M 2022,  [ … ]
Technical analysis
To the publication
Mon, 19.09.2022       Epigenomics AG
DE000A3H2184

Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data to be used as basis for planned PMA submission to FDA Berlin (Germany) and San Diego, CA (U.S.A.), September 19, 2022 - Epigenomics Inc, a wholly-owned subsidia [ … ]
Technical analysis
To the publication
Mon, 19.09.2022       Epigenomics AG
DE000A3H2184

Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data to be used as basis for planned PMA submission to FDA Berlin (Germany) and San Diego, CA (U.S.A.), September 19, 2022 - Epigenomics Inc, a wholly-owned subsidia [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.